Sirtris, a company focused on anti-aging medicine, to be bought by pharm giant Glaxo
Following recent news that Sirtris has promising compounds in the pipeline, GSK buys the young company at an 80% stock premium.
7 votes  by mycophage    0 comments   
Back to:
On Singularity


Join the discussion. Sign up and add your comments.